Envoy Medical (NASDAQ:COCH) Shares Gap Down – Should You Sell?

Envoy Medical, Inc. (NASDAQ:COCH – Get Free Report)’s share price gapped down prior to trading on Monday. The stock had previously closed at $5.9550, but opened at $5.11. Envoy Medical shares last traded at $6.56, with a volume of 23,099 shares.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on COCH shares. HC Wainwright reiterated a “buy” rating on shares of Envoy Medical in a report on Tuesday, October 13th. Lake Street Capital boosted their price objective on shares of Envoy Medical from $2.50 to $25.00 and gave the company a “buy” rating in a research report on Tuesday. Weiss Ratings restated a “sell (e+)” rating on shares of Envoy Medical in a research report on Monday, October 19th. Finally, Loop Capital set a $20.00 price objective on shares of Envoy Medical in a research note on Monday, July 27th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $21.67.

Read Our Latest Report on Envoy Medical

Envoy Medical Price Performance

The company has a market cap of $514.09 million, a PE ratio of -0.88 and a beta of 1.97. The business has a 50 day moving average of $6.91 and a 200 day moving average of $6.88.

Envoy Medical (NASDAQ:COCH – Get Free Report) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.10. The company had revenue of $0.05 million for the quarter, compared to analysts’ expectations of $0.05 million. Sell-side analysts forecast that Envoy Medical, Inc. will post -3.10 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Envoy Medical stock. DSG Capital Advisors LLC purchased a new position in Envoy Medical, Inc. (NASDAQ:COCH – Free Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 625,000 shares of the company’s stock, valued at approximately $416,000. DSG Capital Advisors LLC owned 0.81% of Envoy Medical as of its most recent SEC filing. 8.59% of the stock is currently owned by institutional investors.

About Envoy Medical

(Get Free Report)

Envoy Medical is a medical technology company focused on developing fully implanted hearing devices for people with sensorineural hearing loss. Unlike conventional hearing aids and many cochlear implants, its technology is designed to be placed beneath the skin, with no external wearable sound processor.

The company’s lead product is the Acclaim Cochlear Implant, a fully implanted cochlear implant intended to address moderate-to-profound sensorineural hearing loss in adults. The system is designed to use the body’s natural anatomy to capture sound and convert it into electrical signals that stimulate the auditory nerve.

Recommended Stories

Receive News & Ratings for Envoy Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envoy Medical and related companies with MarketBeat.com's FREE daily email newsletter.